Alimera Sciences, Inc. (ALIM)

Check out top investors' recommendation for ALIM
Last closing price (N/A)
(0.00%) ? 
Last closing price is the stock price upon last market close (date specified in parenthesis).
Return to date (1m/3m/6m/12m):
N/A ? 
Return to date is the stock return for the specified period of time.
Consensus price target (1m/3m/6m/12m):
2.50
 ? 
Consensus price target is the average analyst price target for a specified period of time.
Buy/Sell Mix (1m/3m/6m/12m):
100%/0%
 ? 
Buy/sell mix the percentage mix between Buy and Sell recommendations for a given company or a research firm. Hold recommendations are excluded.
Description:
Alimera Sciences, Inc., a biopharmaceutical company, engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals. The company focuses on diseases affecting the back of the eye or retina. The company’s principal product candidate is ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness. Its ILUVIEN is inserted in the back of the patient’s eye to a placement site that takes advantage of the eye’s natural fluid dynamics to deliver the corticosteroid fluocinolone acetonide (FAc). The company has completed Phase III pivotal clinical trials for the treatment of DME; and in Phase II clinical trials for the treatment of the dry form of age-related macular degeneration and retinal vein occlusion. It has license agreements with pSivida US, Inc. for the development and sale of ILUVIEN; and Dainippon Sumitomo Pharma Co., Ltd. for the development, manufacture, and marketing of an injectable polymer tube implantable into an eye containing a mixture of a polymer and FAc. Alimera Sciences, Inc. was founded in 2003 and is based in Alpharetta, Georgia.
Sector:
Analyst
An analyst is a professional research analyst or an Investor Wand user who issued a recommendation for a given company.
Research Firm
A Research Firm is a company that researches and rates stocks and publishes recommendations.
Signal
Signal is a recommendation issued by an analyst. Investor Wand considers two types of recommendations: BUY and SELL.
Signal Date
A signal date is a date when a BUY or SELL recommendation was issued for given security.
Initial Price
Initial Price is the first closing price for a specified company upon recommendation release. If the recommendation is issued in after-market hours, the Initial Price is the next day’s closing price (for a given symbol). In case of dividend distributions and stock splits, Initial Price is adjusted.
Price Target
A Price Target is an analyst’s projection of a company’s stock price by the end of the recommendation period. It represents the price at which the analyst would exit his or her existing position.
Closing Date
Closing Date is the expiration date of a recommendation. The validity timeframe of a professional analyst’s recommendation is 12 months. Investor Wand analysts can set their recommendation timeframe to one, three, six, or 12 months.
Return
The return on a single open recommendation is calculated as the maximum of the current return (based on the latest closing price) and the target price return, if the symbol reached the target. The return on a single closed recommendation is calculated as the maximum of the return on the closing date (at the end of recommendation timeframe) and the target price return, if the stock hit the target price. The return is adjusted for one-time events (e.g., stock splits).
Ram Selvaraju Aegis Capital Buy   Jun 12, '18     2.50  Jun 12, '19  N/A 
Ram Selvaraju Aegis Capital Buy   Jan 22, '18     5.00  Jan 22, '19  N/A 
Boris Peaker Oppenheimer & Co. Buy   Nov 02, '17     3.00  Nov 02, '18  N/A 
Ram Selvaraju Aegis Capital Buy   Oct 27, '17     5.00  Oct 27, '18  N/A 
Ram Selvaraju Aegis Capital Buy   Aug 30, '17     5.00  Aug 30, '18  N/A 
Boris Peaker Oppenheimer & Co. Buy   Jul 11, '17     3.00  Jul 11, '18  N/A 
Ram Selvaraju Aegis Capital Buy   Jul 11, '17     5.00  Jul 11, '18  N/A 
Boris Peaker Oppenheimer & Co. Buy   Nov 03, '16     3.00  Nov 03, '17  N/A 
Simos Simeonidis Cowen And Company Buy   Sep 16, '16       Sep 16, '17  N/A 
Boris Peaker Oppenheimer & Co. Buy   Mar 03, '16   1.80    Mar 03, '17  N/A 
Boris Peaker Oppenheimer & Co. Buy   Oct 03, '14   5.03    Oct 03, '15  -58.05% 
Simos Simeonidis Cowen And Company Buy   Oct 28, '13   2.08    Oct 28, '14  205.77% 
Christopher Holterhoff Oppenheimer & Co. Buy   Nov 29, '12   2.32  3.00  Nov 29, '13  29.31% 
Amit Bhalla Citi Buy   Dec 26, '10   10.19  12.00  Dec 26, '11  -86.95% 
Christopher Holterhoff Oppenheimer & Co. Buy   Dec 26, '10   10.19  14.00  Dec 26, '11  -86.95%